Clinical Scorecard: Prognostic Implications of Widespread FDG Uptake in Spleen and/or Bone Marrow Linked to Reticuloendothelial System Activation in Patients with Lymphoma

At a Glance

Key Highlights

• FDG PET/CT is crucial for assessing disease burden and treatment response in lymphoma.
• Diffuse FDG uptake in spleen and bone marrow may indicate systemic inflammation.
• Elevated inflammatory markers correlate with aggressive lymphoma behavior and poor survival.
• Misinterpretation of diffuse FDG uptake as tumor infiltration can lead to inappropriate treatment decisions.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

• Consider risks of misinterpretation of diffuse FDG uptake as tumor infiltration, especially in the context of systemic inflammation.

Patient & Prescribing Data

Newly diagnosed, treatment-naïve lymphoma patients.

Individualized treatment strategies based on PET/CT findings and inflammatory markers.

Clinical Best Practices

• Ensure accurate interpretation of PET/CT results by experienced nuclear medicine physicians.
• Exclude patients with confounding conditions affecting splenic/bone marrow metabolism.
• Implement regular training updates for interpreting PET/CT results.

References

• Source Article